Clinical Trial Search

Primary: Number of Participants That Experienced Drug Related Grade 3-4 AEs — 19; 18; 0 Participants

Primary: Part I: Change From Baseline in the Crohn's Disease Activity Index (CDAI) Score at Week 8 — -60.0; -103.6 units on a scale

Primary: Mean 40-Hz Auditory Steady State Response Power — 0.34; 0.43; 0.60 uV^2

Primary: Safety/Tolerability Assessed by Rates of Grade 3 or 4 Post Randomization Adverse Events — 1; 1 Participants

Primary: Number of Participants Until First Non-detectable SARS-CoV-2 in Nasopharyngeal (NP) Swabs — 21; 48; 49; 49 Participants — p=0.5551

Primary: Change From Baseline in Weekly Urticaria Activity Score (UAS7) at Week 4 — -19.10; -19.08; -14.65; -15.99 Scores on a scale — p=<0.0001

Primary: Mean Assay Negativity Rate (ANR) for Ebola Virus During the Treatment Phase — 0.85; 0.76 proportion of semen samples

Primary: Number of Patients With Postoperative Cognitive Dysfunction — 16; 10 Participants — p=0.23

Primary: Change From Baseline in the Integrated Alzheimer's Disease Rating Scale (iADRS) Score — -6.86; -10.06 score on a scale — p=0.042

Primary: Ventilator Free Survival — 58; 19; 44 Participants

Primary: Time-specific Mean Pain Intensity Scores (NRS) at Time 96 Hours for CA-008 vs. Placebo — 3.8; 5.1; 4.9; 4.8 scores on a scale — p=0.276

Primary: Change From Baseline in the Severity of Alopecia Tool (SALT) Score at Week 24 — -6.3; 2.3 score on a scale

Primary: Safety and Tolerability of Multiple Intravenous Infusions of SEL-037 or SEL-212 as Assessed by the Percentage of Participants Experiencing Serious Adverse Events and…

Primary: 1-year Local Progression-free Survival (PFS) — 60 percentage of participants

Primary: Buprenorphine Pharmacokinetics